New UK guidelines may represent a first step toward harmonized global biosimilar development programs without clinical efficacy studies if legal and other hurdles can be overcome.
Guidance issued in May by the Medicines and Healthcare products Regulatory Agency (MHRA) seemingly set a new regulatory standard for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?